Camidanlumab tesirine

Camidanlumab tesirine (Cami-T or ADCT-301) is an antibody-drug conjugate (ADC) composed of a human antibody that binds to the protein CD25, conjugated to a pyrrolobenzodiazepine dimer toxin. The experimental drug, developed by ADC Therapeutics is being tested in clinical trials for the treatment of B-cell Hodgkin's lymphoma (HL) and non-Hodgkin lymphoma (NHL), and for the treatment of B-cell acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).

Camidanlumab tesirine
Monoclonal antibody
Type?
SourceHuman
TargetCD25
Clinical data
Other namesADCT-301
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6548H10150N1732O2038S42
Molar mass147091.83 g·mol−1

Technology

The human monoclonal antibody is conjugated via a cleavable linker to a cytotoxic (anticancer) pyrrolobenzodiazepine (PBD) dimer. The antibody binds to CD25, which is the alpha chain of the interleukin 2 receptor IL2RA. This molecule is expressed mainly on activated T- and B-cells, both of which are types of white blood cells that play a role in the human immune system. CD25 is over-expressed in a wide range of hematological malignancies, such as leukemias and lymphomas.[1][2] After binding to a CD25-expressing cell, the antibody is internalized into the cell where enzymes release the cytotoxic drug. PBD dimers work by crosslinking specific sites of the DNA, blocking the cancer cells’ division that cause the cells to die. As a class of DNA-crosslinking agents they are significantly more potent than systemic chemotherapeutic drugs.[3]

Clinical trials

Two phase I trials are evaluating the drug in patients with relapsed or refractory Hodgkin’s and non-Hodgkin’s lymphoma and relapsed or refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia.[4][5] At the 59th American Society of Hematology (ASH) Annual Meeting, interim results from a Phase I, open-label, single agent dose-escalating study designed to evaluate the treatment of camidanlumab tesirine in relapsed or refractory Hodgkin’s or non-Hodgkin’s lymphoma were presented. Among the patients enrolled at the time of the data cutoff the overall response rate was 78% (including a 44% complete response rate) in patients with relapsing or refractory Hodgkin’s lymphoma.[6]

gollark: My static site's faster than a dynamic one and can run on a server without much configuration.
gollark: ...
gollark: Well, I would recommend using a static site generator of some kind.
gollark: Well, obviously you should add more of these (https://kspalaiologos.now.im/img/ie_logo.gif) excellent banners, including animated ones.
gollark: You know you can't style the button on `<input type=file>` *at all*?

References
  1. Schnell R, Vitetta E, Schindler J, Barth S, Winkler U, Borchmann P, et al. (August 1998). "Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma". Leukemia & Lymphoma. 30 (5–6): 525–37. doi:10.3109/10428199809057565. PMID 9711915.
  2. Nakase K, Kita K, Miwa H, Nishii K, Shikami M, Tanaka I, et al. (February 2007). "Clinical and prognostic significance of cytokine receptor expression in adult acute lymphoblastic leukemia: interleukin-2 receptor alpha-chain predicts a poor prognosis". Leukemia. 21 (2): 326–32. doi:10.1038/sj.leu.2404497. PMID 17205058.
  3. "Pyrrolobenzodiazepine". adcreview.com.
  4. Clinical trial number NCT02432235 for "Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma" at ClinicalTrials.gov
  5. Clinical trial number NCT02588092 for "Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)" at ClinicalTrials.gov
  6. "Interim Results from a Phase 1 Study of ADCT-301 (Camidanlumab Tesirine) Show Promising Activity of a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate in Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma" (PDF). adctherapeutics.com. Archived from the original (PDF) on 2018-03-08. Retrieved 2018-01-23.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.